

REMARKS

Claims 148-203 have been canceled without prejudice or disclaimer. Claims 204-206 have been added and therefore are pending in the present application. Claims 204-206 are supported by claims 148-203.

The Advisory Action refused to enter the amendment filed March 2, 2004 because it raised new issues. Specifically, the Office stated that "The scope of the claims has been changed by the amendment requiring additional consideration. Claims 204-206 would require the 112, 2nd paragraph, rejection because the reference to SEQ ID NO: 1 renders the claims unclear. Further claims 205-206 are incomplete as dependent from canceled claim 148." This is respectfully traversed.

The reference to SEQ ID NO: 1 was included in claim 148. Therefore, this does not raise a new issue. Furthermore, the reference to SEQ ID NO: 1 is not unclear. As described at pages 5-11 of the specification, SEQ ID NO: 1 is used to identify the positions recited in the claims.

New claims 205-206 depend from claim 204. Therefore, this objection has been overcome.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the remarks set forth in the Amendment filed March 2, 2004 is requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Date: March 31, 2004